Advertisement

Advertisement

GYRE Stock Latest News

Gyre Therapeutics Secures CEO and CFO with New Contracts

Company AnnouncementsGyre Therapeutics Secures CEO and CFO with New Contracts

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

PremiumCompany Announcements

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

2M ago

Gyre Therapeutics unveils capital-efficient global development strategy

PremiumCompany Announcements

Gyre Therapeutics unveils capital-efficient global development strategy

2M ago

Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks

PremiumCompany Announcements

Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks

2M ago

Gyre Therapeutics Strengthens Board with New Director Appointments

PremiumCompany Announcements

Gyre Therapeutics Strengthens Board with New Director Appointments

3M ago

Gyre Therapeutics files to sell 30.22M shares of common stock for holders

PremiumThe FlyGyre Therapeutics files to sell 30.22M shares of common stock for holders

4M ago

Gyre Therapeutics Shareholders Approve Directors and Governance Measures

Company Announcements

Gyre Therapeutics Shareholders Approve Directors and Governance Measures

4M ago

Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy

Company Announcements

Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy

5M ago

Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion

PremiumCompany Announcements

Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion

5M ago

Gyre Therapeutics’ F351 NDA Accepted for Priority Review

PremiumCompany Announcements

Gyre Therapeutics’ F351 NDA Accepted for Priority Review

5M ago

Gyre Therapeutics announces China NMPA acceptance of F351 NDA

PremiumThe Fly

Gyre Therapeutics announces China NMPA acceptance of F351 NDA

5M ago

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

PremiumThe Fly

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

6M ago

GYRE Upcoming Earnings Report: What to Expect?

PremiumPre-EarningsGYRE Upcoming Earnings Report: What to Expect?

6M ago

Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition

Company Announcements

Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition

6M ago

Gyre Therapeutics Files NDA in China for F351

Company Announcements

Gyre Therapeutics Files NDA in China for F351

7M ago

Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval

PremiumRatings

Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval

7M ago

Gyre Therapeutics’ liver fibrosis candidate granted priority review in China

PremiumThe Fly

Gyre Therapeutics’ liver fibrosis candidate granted priority review in China

7M ago

Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions

PremiumCompany Announcements

Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions

7M ago

Gyre Therapeutics Projects Strong Growth for Fibrosis Programs

PremiumCompany Announcements

Gyre Therapeutics Projects Strong Growth for Fibrosis Programs

8M ago

Gyre Therapeutics reports Q4 EPS (2c), consensus 1c

PremiumThe FlyGyre Therapeutics reports Q4 EPS (2c), consensus 1c

8M ago

Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M

The Fly

Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M

8M ago

Gyre Therapeutics to Acquire Cullgen in All-Stock Merger

Company Announcements

Gyre Therapeutics to Acquire Cullgen in All-Stock Merger

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >